NCT06329739Recruiting
Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes
Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes in Patients Undergoing Dopaminergic Treatment
Source: ClinicalTrials.gov · Last updated 26 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD. The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients. Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years. Researchers will compare data collected from patients with genetic mutation versus patients without mutation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 68 (estimated)
- First submitted
- 6 Mar 2024
- Start date
- 14 Dec 2021
- Primary completion date
- 14 Dec 2031
- Lead sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- Diseases
- Parkinson disease
- NCT number
- NCT06329739
What you commit to
- Study type: Observational
- Planned participants: 68
- From 14 Dec 2021 to the primary completion date, 14 Dec 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients underwent Deep Brain Stimulation (DBS) treatment
Who the study is looking for
- diagnosed with Parkinson's Disease (PD)
- in use of dopaminergic medication (L-Dopa and/or dopamine agonists)
- genetic testing for mendelian forms of PD
- able to provide informed consent to participate in the study
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.